Compared to Estimates, Sotera Health (SHC) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2025, Sotera Health Company (SHC) reported revenue of $294.34 million, up 6.4% over the same period last year. EPS came in at $0.20, compared to $0.19 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $276.08 million, representing a surprise of +6.61%. The company delivered an EPS surprise of +17.65%, with the consensus EPS estimate being $0.17.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Sotera Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Revenues- Sterigenics: $194.84 million compared to the $184.48 million average estimate based on two analysts. The reported number represents a change of +10.5% year over year.
• Net Revenues- Nelson Labs: $57.07 million versus the two-analyst average estimate of $56.73 million. The reported number represents a year-over-year change of -3.3%.
• Net Revenues- Nordion: $42.43 million compared to the $34.95 million average estimate based on two analysts. The reported number represents a change of +2.9% year over year.
• Segment Income- Sterigenics: $107.75 million compared to the $100.36 million average estimate based on two analysts.
• Segment Income- Nelson Labs: $19.51 million versus $17.53 million estimated by two analysts on average.
• Segment Income- Nordion: $23.48 million versus the two-analyst average estimate of $18.62 million.

View all Key Company Metrics for Sotera Health here>>>

Shares of Sotera Health have returned -5.6% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Sotera Health Company (SHC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research